Results 41 to 50 of about 345,374 (311)
Lupus anticoagulant is frequent in patients with Covid‐19: Response to Reply
Journal of Thrombosis and Haemostasis, 2020 We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid‐19 patients (1). Different authors had confirmed these results (2).
I. Harzallah, A. Debliquis, B. Drénou
semanticscholar +1 more source
Influence of anticardiolipin and anti-β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification [PDF]
, 2019 Background: Anticardiolipin (aCL) and anti-beta 2 glycoprotein I (a beta 2GPI) immunoglobulin (Ig) G/IgM antibodies are 2 of the 3 laboratory criteria for classification of antiphospholipid syndrome (APS).
de Laat, Bas +4 more
core +3 more sources
Experimental Biology and Medicine, 1984 Lupus-like anticoagulant (LLAC) is the term used to identify an acquired inhibitor (1) of blood coagulation, first described by Conley and Hartmann in patients with systemic lupus erythematosus (SLE) (2). A circulating “lupus-like” anticoagulant has been detected in 5-10% of all SLE patients.
N, Perico, F, Pusineri, G, Remuzzi
openaire +2 more sources
Clinical Rheumatology, 2020 About 15–20% of patients with severe acute respiratory syndrome–coronavirus 2 (SARS-CoV2) disease experience pneumonia of variable extent and course [1]. A proportion of them have cardiovascular involvement, including myocarditis, ischemia and shock, and
C. Gazzaruso +6 more
semanticscholar +1 more source
Thrombosis Journal, 2006 Background Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT, RVVT or dPT clotting times. If a patient is being treated with
Wisløff Finn +3 more
doaj +1 more source
Loss of antiphospholipid antibody positivity post-thrombosis in SLE
Lupus Science and Medicine, 2020 Background/Purpose Loss of positivity of antiphospholipid antibodies has been observed in clinical practice post-thrombosis in patients with SLE with secondary antiphospholipid syndrome (APS). Our study defined the frequency of this loss and the duration
Muznay Khawaja
doaj +1 more source
Loss of maternal annexin A5 increases the likelihood of placental platelet thrombosis and foetal loss [PDF]
, 2012 Antiphospholipid syndrome is associated with an increased risk of thrombosis and pregnancy loss. Annexin A5 (Anxa5) is a candidate autoantigen. It is not known, however, whether endogenous Anxa5 prevents foetal loss during normal pregnancy.
Brachvogel, Bent +11 more
core +1 more source
Journal of Thrombosis and Haemostasis, 2020 Direct oral anticoagulants (DOACs) interfere with lupus anticoagulant (LAC) testing. DOAC‐Stop (D‐S) represents a preanalytical strategy to cope with this issue.
Pieter M M De Kesel, K. Devreese
semanticscholar +1 more source
Cognitive dysfunction improves in systemic lupus erythematosus: Results of a 10 years prospective study [PDF]
, 2018 Objective Cognitive impairment (CI) has been described in 3–80% of Systemic lupus erythematosus (SLE) patients but only short-term studies evaluated its over-time changes, suggesting that CI is usually a stable finding. We aimed at evaluating the changes
Alessandri, Cristiano +9 more
core +2 more sources
Lupus anticoagulant and mortality in patients hospitalized for COVID-19
Journal of Thrombosis and Thrombolysis, 2020 Coronavirus disease 2019 (COVID-19) is characterized by a procoagulant state that can lead to fatal thromboembolic events. Several studies have documented a high prevalence of lupus anticoagulant that may at least partially explain the procoagulant ...
C. Gazzaruso +10 more
semanticscholar +1 more source